Exploring the Credibility of Psilocybin-assisted Therapy and Cognitive-behavioral Therapy for Depression
Brianna R. Altman, Mitch Earleywine, Joseph A. de Leo
Journal of Psychoactive Drugs January 3, 2022 DOI: 10.1080/02791072.2021.2020382 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 803 |
| Population | Adults reporting depressive symptoms recruited from Amazon's MTurk platform |
| Interventions | Cognitive-behavioral therapy Psilocybin-assisted therapy |
| Topics | Psilocybin Depression |
| Keywords | Credibility Psychological intervention Clinical psychology Depression economics Cognitive behavioral therapy Cognitive therapy Psychotherapist Cognition Hallucinogen |
| Citations | 4 |
| Key findings | Individuals rated CBT as more credible than PAT, and those with therapy experience rated CBT higher than those without. |
Abstract
Depression treatments succeed with many but leave others unimproved, and they can generate concerns about side effects, time, and cost. Psilocybin has generated media attention and empirical support for antidepressant effects, but lay impressions of its effectiveness are unclear. Although perceptions of treatment credibility contribute to outcome, beliefs about the credibility of psilocybin-assisted therapy (PAT) among potential patients remain uninvestigated, especially relative to cognitive-behavioral therapy (CBT), a common, empirically-validated approach. The present study examined credibility ratings for CBT and PAT among individuals reporting depressive symptoms. Participants (N = 803) from Amazon's MTurk platform reported demographics, depressive symptoms, and psychotherapy experience, then read data-based vignettes describing each therapy and rated their credibility. Individuals rated CBT as more credible than PAT. Those with therapy experience rated CBT as more credible than those without. Men and lifetime hallucinogen users rated PAT more credible than women and non-users, but few other predictors accounted for much variance in credibility. Results suggest that potential clients appear cautious about PAT. As continued work examines the effectiveness of psychedelic-assisted interventions, researchers and clinicians must consider patients' beliefs about treatments as potential predictors of outcomes. Additionally, the paradigm used here might have potential for examining credibility of many interventions.
Comparable studies
Other cross-sectional and survey studies on psilocybin for depression, most cited first.
Citations in the library
Cited by 3
- Expectancies for Subjective and Antidepressant Effects in Psilocybin Users Journal of Humanistic Psychology September 22, 2023
- Perceptions of Psilocybin-Assisted Psychotherapy and Standard Interventions for Nicotine Cessation Journal of Psychoactive Drugs 2026
- Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectancies
Cites 26
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology November 8, 2017
and 21 more in the library